The world of biopharma has witnessed remarkable transformations, especially when it comes to companies entering public markets. Recently, Kailera Therapeutics achieved a historic milestone by raising $625 million in its initial public offering (IPO), setting a new record for the largest public market debut in the industry.
The Genesis of Biopharma IPOs
Biopharma’s journey into public markets began in 1980 with the pioneering IPO of Genentech. The company offered one million shares at $35 each, and at the time, The Wall Street Journal hailed it as “one of the most spectacular market debuts in recent history.” Genentech returned to the public markets in 1999, raising nearly $2 billion after Roche, a major shareholder, restructured its stake in the company. Today, Genentech remains a cornerstone of Roche’s drug development efforts and is celebrated as one of the most successful biotech entities in history.
Shifting Market Dynamics
In recent years, the path to public markets has become increasingly challenging. The post-pandemic landscape has led to a significant reduction in biopharma IPOs, with only eight companies going public in the previous year—the lowest number in at least five years. However, 2026 is showing signs of recovery, with ten companies already making their public debut or initiating offerings in just the first quarter, surpassing the total for all of 2025.
Kailera Therapeutics’ Record-Breaking IPO
Among these newly public companies, Kailera Therapeutics has captured the industry’s attention. The Massachusetts-based firm made headlines in October 2024 by raising $400 million in a Series A funding round focused on developing obesity treatments. Following this success, Kailera aimed for the Nasdaq Global Select Market and set its sights on raising up to $533 million. The company ultimately surpassed expectations, amassing $625 million and establishing itself as a leader in the biopharma IPO space.
Pioneering Obesity Treatments
Kailera’s IPO was driven by its focus on obesity, a sector that has seen a surge in investment. According to J.P. Morgan, biopharma companies committed approximately $22 billion to obesity and diabetes licensing deals in the first quarter of this year alone. This figure already exceeds the total deal value for all of 2025 and doesn’t include acquisition values.
Leading Kailera’s pipeline is ribupatide, a dual agonist targeting GLP-1 and GIP receptors, developed in collaboration with Jiangsu Hengrui Pharmaceuticals. Recent Phase 2 trials showed promising results, with patients experiencing a 12.1% weight reduction, prompting Kailera to advance ribupatide into Phase 3 development.
The Rise of Moderna
Another significant player in the IPO landscape is Moderna, which raised $604 million in December 2018. The company, founded in 2010, gained immense attention during the COVID-19 pandemic due to its mRNA technology. Moderna’s COVID-19 vaccine, Spikevax, achieved remarkable sales, solidifying its position as a market leader. However, the post-pandemic era has posed challenges, with the company’s market cap decreasing significantly as it struggles to replicate its earlier success with new products.
Sana Biotechnology’s Ambitious Start
Sana Biotechnology made waves in February 2021 with a $587.5 million IPO, initially targeting a much lower fundraising goal. The company focuses on cell therapies for diabetes and cancer, utilizing innovative engineering technologies. Despite some initial successes, Sana has faced hurdles, including the need to prioritize certain development programs over others, showcasing the unpredictable nature of the biopharma industry.
Acelyrin’s Rollercoaster Journey
Acelyrin, which went public in May 2023 with a $540 million IPO, initially sparked optimism in a recovering market. The company’s lead asset, izokibep, was positioned as a potential treatment for several immune disorders. However, disappointing phase trials led Acelyrin to reevaluate its strategy, culminating in a controversial merger with Alumis in 2025. This merger faced backlash from shareholders, highlighting the complexities of navigating partnerships in the biopharma space.
Recursion’s Tech-Driven Approach
Lastly, Recursion, which went public in April 2021 with a $436.4 million IPO, is notable for its use of artificial intelligence in drug development. The company’s proprietary Recursion Operating System guides the drug discovery process. While Recursion has attracted considerable attention and partnerships, it has also encountered workforce reductions as it refines its strategies to adapt to the evolving market landscape.
Conclusion
The biopharma IPO landscape is marked by both triumphs and challenges, reflecting the dynamic nature of the industry. Companies like Kailera Therapeutics and Moderna illustrate the potential for groundbreaking advancements but also highlight the volatility that can accompany rapid growth. As the market continues to evolve, the successes and setbacks of these biopharma firms will shape the future of public offerings in this critical sector.
- Kailera Therapeutics set a record with a $625 million IPO.
- Moderna’s IPO raised $604 million, but the company faces post-pandemic challenges.
- Sana Biotechnology’s ambitious start led to a $587.5 million IPO amid evolving strategies.
- Acelyrin’s journey underscores the complexities of mergers in the biopharma sector.
- Recursion leverages AI for drug development, showcasing a tech-driven approach to biopharma.
Read more → www.biospace.com